Clinical adoption patterns of 0.35 Tesla MR-guided radiation therapy in Europe and Asia.
Fiche publication
Date publication
août 2022
Journal
Radiation oncology (London, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr QUIVRIN Magali
Tous les auteurs :
Slotman BJ, Clark MA, Özyar E, Kim M, Itami J, Tallet A, Debus J, Pfeffer R, Gentile P, Hama Y, Andratschke N, Riou O, Camilleri P, Belka C, Quivrin M, Kim B, Pedersen A, van Overeem Felter M, Kim YI, Kim JH, Fuss M, Valentini V
Lien Pubmed
Résumé
Magnetic resonance-guided radiotherapy (MRgRT) utilization is rapidly expanding, driven by advanced capabilities including better soft tissue imaging, continuous intrafraction target visualization, automatic triggered beam delivery, and the availability of on-table adaptive replanning. Our objective was to describe patterns of 0.35 Tesla (T)-MRgRT utilization in Europe and Asia among early adopters of this novel technology.
Mots clés
ART, Care patterns, MR-IGRT, MRI-guided radiotherapy, On-table adaptive radiation therapy, SABR, SBRT, Stereotactic ablative radiation therapy, Stereotactic body radiotherapy, oART
Référence
Radiat Oncol. 2022 08 22;17(1):146